Pulmonary Disease, Chronic Obstructive
Conditions
Brief summary
Study to demonstrate the comparability of two puffs of Combivent hydrofluoroalkane (HFA) inhalation aerosol (18 mcg ipratropium bromide/100 mcg albuterol sulfate / per puff) to two puffs of the marketed chlorofluorocarbon (CFC) containing product, Combivent (CFC) inhalation aerosol (18 mcg ipratropium bromide/103 mcg albuterol sulfate / per puff). The dose response profile, safety and pharmacokinetics of Combivent HFA formulation are to be characterized.
Interventions
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. All patients were to have a diagnosis of COPD and must have met the following criteria at visit 1: Patients were to have relatively stable, moderate to severe airway obstruction with a baseline forced expiratory volume in one second (FEV1) \<=65 % of predicted normal and FEV1 / forced vital capacity (FVC) \<=70 %. 2. Patients must have demonstrated a \>= 015 % improvement in baseline FEV1 within one hour after the inhalation of two puffs of Combivent (CFC) inhalation aerosol (18 mcg ipratropium bromide/103 mcg albuterol sulfate per actuation; ex-mouthpiece dose) 3. Male or female patients 40 years of age or older. 4. Patients must have had a smoking history of more than ten pack-year. A pack-year is defined as the equivalent of smoking on pack of 20 cigarettes per day for a year. 5. Patients must have been able to perform technical satisfactory pulmonary function test. 6. Patients must have been able to be trained in the proper use of a metered dose inhalator (MDI) 7. All patients must have signed an informed consent form prior to participation in the trial i.e., prior to pre-study washout of their usual pulmonary medications.
Exclusion criteria
1. Patients with significant disease other than COPD were to be excluded. A significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study. 2. Patients with clinical relevant abnormal baseline hematology, blood chemistry or urinalysis. If the abnormality defined a disease listed as an exclusion criterion, the patient was to be excluded. 3. All patients with a serum glutamic-oxaloacetic transaminase (SGOT) \> 80 IU/L, serum glutamic pyruvic transaminase (SGPT) \> 80 IU/L, bilirubin \> 2.0 mg/dL or creatinine \> 2.0 mg/dL were to be excluded regardless of the clinical condition. Repeat laboratory evaluation was not to be conducted in these patients. 4. Patients who had total blood eosinophil count \>= 600/mm³. A repeat eosinophil count was not to be conducted in these patients. 5. Patients with a recent history (i.e., one year or less) of myocardial infarction. 6. Patients with a recent history (i.e., three years or less) of heart failure or patients with any cardiac arrhythmia requiring drug therapy. 7. Patients with a history of cancer, other than treated basal cell carcinoma, within the last five years. 8. Patients with a history of life threatening pulmonary obstruction, or a history of cystic fibrosis or bronchiectasis. 9. Patients who have undergone thoracotomy with pulmonary resection. Patients with a history or a thoracotomy for other reasons were to be evaluated as per
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Average forced expiratory volume in the first second (FEV1) response calculated as area under the curve above test-day baseline from time 0 to 6 hours divided by six (AUC0-6h) | 0, 1, 2, 3, 4, 5 and 6 hours post drug administration |
Secondary
| Measure | Time frame |
|---|---|
| albuterol plasma concentration (AUC0-8h) | 5, 15, 30 minutes and 1, 2, 4 and 8 hours post drug administration |
| number of patients with Adverse Events | up to day 49 after first drug administartion |
| change from baseline in pulse rate and blood pressure | up to day 49 after first drug administartion |
| albuterol plasma concentration | pre-treatment; 5, 15, 30 minutes and 1, 2, 4 and 8 hours post drug administration |
| ipratropium amount from renal excretion (Ae0-2, Ae0-8) | pre-treatment, 0 to 2 hours and 2 to 8 hours post drug administration |
| albuterol amount from renal excretion (Ae0-2, Ae0-8) | pre-treatment, 0 to 2 hours and 2 to 8 hours post drug administration |
| onset of therapeutic FEV1 response | up to 8 hours post drug administration |
| peak FEV1 | up to 8 hours post drug administration |
| ipratropium plasma concentration (AUC0-8h) | 5, 15, 30 minutes and 1, 2, 4 and 8 hours post drug administration |
| average of FEV1, pictured as area under the curve (AUC0-8h) | 0, 1, 2, 3, 4, 5, 6 and 8 hours post drug administration |
| individual FEV1 | 0, 1, 2, 3, 4, 5, 6 and 8 hours post drug administration |
| individual forced vital capacity (FVC) | 0, 1, 2, 3, 4, 5, 6 and 8 hours post drug administration |
| average of FVC, pictured as area under the curve (AUC0-8h) | 0, 1, 2, 3, 4, 5, 6 and 8 hours post drug administration |
| peak FVC | up to 8 hours post drug administration |
| ipratropium plasma concentration | pre-treatment; 5, 15, 30 minutes and 1, 2, 4 and 8 hours post drug administration |
| change from baseline in physical examination, laboratory test and 12-lead ECG | up to day 49 after first drug administartion |
| time to peak FEV1 | up to 8 hours post drug administration |
Outcome results
None listed